Farr Miller & Washington’s VanEck Pharmaceutical ETF PPH Stock Holding History

Farr Miller & Washington’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-4,000	Closed	-$210K	–	152
2016 Q4	$210K	Hold	4,000	–	–	0.02%	132
2016 Q3	$229K	Hold	4,000	–	–	0.02%	125
2016 Q2	$234K	Hold	4,000	–	–	0.03%	119
2016 Q1	$230K	Hold	4,000	–	–	0.03%	125
2015 Q4	$261K	Hold	4,000	–	–	0.03%	111
2015 Q3	$252K	Hold	4,000	–	–	0.03%	110
2015 Q2	$283K	Hold	4,000	–	–	0.03%	112
2015 Q1	$281K	Hold	4,000	–	–	0.03%	115
2014 Q4	$257K	Hold	4,000	–	–	0.03%	113
2014 Q3	$254K	Hold	4,000	–	–	0.03%	107
2014 Q2	$248K	Hold	4,000	–	–	0.03%	125
2014 Q1	$233K	Buy	+4,000	New	+$226K	0.03%	114

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SCM

Stuyvesant Capital Management Armonk, New York $41.1M AUM 17.11% 1-Year Est. Return

Colrain Capital Boston, Massachusetts $259M AUM 63.6% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Farr Miller & Washington's PPH Position: Q1 2017 in Review

Farr Miller & Washington sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2017, closing a stake of 4,000 shares — an estimated $210K sold.

Farr Miller & Washington first reported a position in PPH in Q1 2014 and held it in 12 quarters. The position peaked at $283K in Q2 2015. 50 funds tracked by Wall St. Rank hold PPH as of Q1 2017.

Farr Miller & Washington reported no remaining VanEck Pharmaceutical ETF position as of Q1 2017 after selling out during the quarter.
Farr Miller & Washington sold 4,000 VanEck Pharmaceutical ETF shares in Q1 2017, an estimated $210K.
Farr Miller & Washington first reported a position in VanEck Pharmaceutical ETF in Q1 2014 and held it in 12 quarters.
Farr Miller & Washington's VanEck Pharmaceutical ETF position peaked at $283K in Q2 2015.
50 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2017.

Based on Farr Miller & Washington's 13F filing for Q1 2017, filed 12 May 2017.